AU5163799A - Use of alfuzosin for the manufacture of drugs intended for the treatment of disorders induced by smooth muscle contraction in the urinary tract, excluding contraction of alpha-adrenergic origin - Google Patents

Use of alfuzosin for the manufacture of drugs intended for the treatment of disorders induced by smooth muscle contraction in the urinary tract, excluding contraction of alpha-adrenergic origin

Info

Publication number
AU5163799A
AU5163799A AU51637/99A AU5163799A AU5163799A AU 5163799 A AU5163799 A AU 5163799A AU 51637/99 A AU51637/99 A AU 51637/99A AU 5163799 A AU5163799 A AU 5163799A AU 5163799 A AU5163799 A AU 5163799A
Authority
AU
Australia
Prior art keywords
contraction
alfuzosin
adrenergic
excluding
origin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51637/99A
Inventor
Ralph Eckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU5163799A publication Critical patent/AU5163799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU51637/99A 1998-07-28 1999-07-23 Use of alfuzosin for the manufacture of drugs intended for the treatment of disorders induced by smooth muscle contraction in the urinary tract, excluding contraction of alpha-adrenergic origin Abandoned AU5163799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98401917 1998-07-28
EP98401917 1998-07-28
PCT/EP1999/005278 WO2000006168A1 (en) 1998-07-28 1999-07-23 USE OF ALFUZOSIN FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF DISORDERS INDUCED BY SMOOTH MUSCLE CONTRACTION IN THE URINARY TRACT, EXCLUDING CONTRACTION OF α-ADRENERGIC ORIGIN

Publications (1)

Publication Number Publication Date
AU5163799A true AU5163799A (en) 2000-02-21

Family

ID=8235455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51637/99A Abandoned AU5163799A (en) 1998-07-28 1999-07-23 Use of alfuzosin for the manufacture of drugs intended for the treatment of disorders induced by smooth muscle contraction in the urinary tract, excluding contraction of alpha-adrenergic origin

Country Status (2)

Country Link
AU (1) AU5163799A (en)
WO (1) WO2000006168A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001288115A (en) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd Remedy for lower urinary tract symptom

Also Published As

Publication number Publication date
WO2000006168A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
ZA200200738B (en) Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity.
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
SI1432701T1 (en) Heterocyclic compounds for use in the treatment of disorders of the urinary tract
IL176968A0 (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU6910600A (en) Methods for the treatment of mental disorders
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003223172A1 (en) Use of the axl receptor for diagnosis and treatment of renal disease
EP1440689A3 (en) Treatment of neurotic disorders
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
WO2002043715A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
MXPA03003032A (en) Combination therapy for the treatment of estrogen-sensitive disease.
AU5163799A (en) Use of alfuzosin for the manufacture of drugs intended for the treatment of disorders induced by smooth muscle contraction in the urinary tract, excluding contraction of alpha-adrenergic origin
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
ZA200405173B (en) 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence.
IL162524A (en) Derivatives of 5- (pyridin- 3 - yl)-1 - azabicyclo [3.2.1] octane, their preparation and their therapeutic application
WO2001007038A3 (en) Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
WO2002043712A3 (en) Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase